Recent Findings and Future Directions for Interpolar Mitotic Kinesin Inhibitors in Cancer Therapy

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2016 Mar 16

PMID 26976726

Citations 42

Authors

Stephanie M Myers

Ian Collins

Affiliations

Soon will be listed here.

Abstract

The kinesin class of microtubule-associated motor proteins present attractive anticancer targets owing to their roles in key functions in dividing cells. Two interpolar mitotic kinesins Eg5 and HSET have opposing motor functions in mitotic spindle assembly with respect to microtubule movement, but both offer opportunities to develop cancer selective therapeutic agents. Here, we summarize the progress to date in developing inhibitors of Eg5 and HSET, with an emphasis on structural biology insights into the binding modes of allosteric inhibitors, compound selectivity and mechanisms of action of different chemical scaffolds. We discuss translation of preclinical studies to clinical experience with Eg5 inhibitors, recent findings on potential resistance mechanisms and explore the implications for future anticancer drug development against these targets.

Citing Articles

Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer.

Zhang C, Wu B, Thu K Cancers (Basel). 2025; 17(4).

PMID: 40002279 PMC: 11853690. DOI: 10.3390/cancers17040685.

KIFC3 promotes the progression of non-small cell lung cancer cells through the PI3K/Akt pathway.

Mu Y, Liu H, Luo A, Zhang Q Thorac Cancer. 2024; 15(33):2356-2364.

PMID: 39390964 PMC: 11586134. DOI: 10.1111/1759-7714.15465.

Identifying and characterising promising small molecule inhibitors of kinesin spindle protein using ligand-based virtual screening, molecular docking, molecular dynamics and MM‑GBSA calculations.

Elseginy S J Comput Aided Mol Des. 2024; 38(1):16.

PMID: 38556596 PMC: 10982093. DOI: 10.1007/s10822-024-00553-5.

Requirement of microtubules for secretion of a micronemal protein CpTSP4 in the invasive stage of the apicomplexan .

Wang D, Jiang P, Wu X, Zhang Y, Wang C, Li M mBio. 2024; 15(2):e0315823.

PMID: 38265238 PMC: 10865969. DOI: 10.1128/mbio.03158-23.

Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.

Kumari S, Raj S, Babu M, Bhatti G, Bhatti J Arch Pharm Res. 2023; 47(1):40-65.

PMID: 38153656 DOI: 10.1007/s12272-023-01479-6.

References

Cross R, McAinsh A . Prime movers: the mechanochemistry of mitotic kinesins. Nat Rev Mol Cell Biol. 2014; 15(4):257-71. DOI: 10.1038/nrm3768. View

Matsuno K, Sawada J, Sugimoto M, Ogo N, Asai A . Bis(hetero)aryl derivatives as unique kinesin spindle protein inhibitors. Bioorg Med Chem Lett. 2009; 19(4):1058-61. DOI: 10.1016/j.bmcl.2009.01.018. View

Sun D, Lu J, Ding K, Bi D, Niu Z, Cao Q . The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma. Med Oncol. 2013; 30(1):476. DOI: 10.1007/s12032-013-0476-0. View

Komlodi-Pasztor E, Sackett D, Tito Fojo A . Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res. 2012; 18(1):51-63. DOI: 10.1158/1078-0432.CCR-11-0999. View

Bender A, Young D, Jenkins J, Serrano M, Mikhailov D, Clemons P . Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb Chem High Throughput Screen. 2007; 10(8):719-31. DOI: 10.2174/138620707782507313. View

Wakui H, Yamamoto N, Kitazono S, Mizugaki H, Nakamichi S, Fujiwara Y . A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 74(1):15-23. DOI: 10.1007/s00280-014-2467-z. View

Bakr El-Nassan H . Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J Med Chem. 2013; 62:614-31. DOI: 10.1016/j.ejmech.2013.01.031. View

Theoclitou M, Aquila B, Block M, Brassil P, Castriotta L, Code E . Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent. J Med Chem. 2011; 54(19):6734-50. DOI: 10.1021/jm200629m. View

Wood K, Lad L, Luo L, Qian X, Knight S, Nevins N . Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A. 2010; 107(13):5839-44. PMC: 2851928. DOI: 10.1073/pnas.0915068107. View

10.

Chandrasekaran G, Tatrai P, Gergely F . Hitting the brakes: targeting microtubule motors in cancer. Br J Cancer. 2015; 113(5):693-8. PMC: 4559828. DOI: 10.1038/bjc.2015.264. View

11.

Takeuchi T, Oishi S, Watanabe T, Ohno H, Sawada J, Matsuno K . Structure-activity relationships of carboline and carbazole derivatives as a novel class of ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2011; 54(13):4839-46. DOI: 10.1021/jm200448n. View

12.

Klabunde T . Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br J Pharmacol. 2007; 152(1):5-7. PMC: 1978276. DOI: 10.1038/sj.bjp.0707308. View

13.

Wang F, Good J, Rath O, Kaan H, Sutcliffe O, Mackay S . Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity. J Med Chem. 2012; 55(4):1511-25. PMC: 3428805. DOI: 10.1021/jm201195m. View

14.

Talapatra S, Anthony N, Mackay S, Kozielski F . Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. J Med Chem. 2013; 56(16):6317-29. DOI: 10.1021/jm4006274. View

15.

Good J, Skoufias D, Kozielski F . Elucidating the functionality of kinesins: an overview of small molecule inhibitors. Semin Cell Dev Biol. 2011; 22(9):935-45. DOI: 10.1016/j.semcdb.2011.09.023. View

16.

LoRusso P, Goncalves P, Casetta L, Carter J, Litwiler K, Roseberry D . First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015; 33(2):440-9. DOI: 10.1007/s10637-015-0211-0. View

17.

Rice S, Lin A, Safer D, Hart C, Naber N, Carragher B . A structural change in the kinesin motor protein that drives motility. Nature. 2000; 402(6763):778-84. DOI: 10.1038/45483. View

18.

Cochran J, Gatial 3rd J, Kapoor T, Gilbert S . Monastrol inhibition of the mitotic kinesin Eg5. J Biol Chem. 2005; 280(13):12658-67. PMC: 1356610. DOI: 10.1074/jbc.M413140200. View

19.

Ogo N, Ishikawa Y, Sawada J, Matsuno K, Hashimoto A, Asai A . Structure-Guided Design of Novel l-Cysteine Derivatives as Potent KSP Inhibitors. ACS Med Chem Lett. 2015; 6(9):1004-9. PMC: 4569872. DOI: 10.1021/acsmedchemlett.5b00221. View

20.

McGrath M, Kuo I, Hayashi S, Takada S . Adenosine triphosphate hydrolysis mechanism in kinesin studied by combined quantum-mechanical/molecular-mechanical metadynamics simulations. J Am Chem Soc. 2013; 135(24):8908-19. DOI: 10.1021/ja401540g. View